Healthcare
•3753 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3753)
| Company | Market Cap | Price |
|---|---|---|
|
ALUR
Allurion Technologies Inc.
Connected scale and home health monitoring capabilities via VCS/Allurion ecosystem.
|
$14.36M |
$1.84
-2.65%
|
|
TRAW
Traws Pharma, Inc.
Company is developing Antiviral Small-Molecule Therapeutics (ratutrelvir) for COVID-19 as a core antiviral program.
|
$14.27M |
$2.01
+16.86%
|
|
FBLG
FibroBiologics, Inc. Common Stock
Core business is fibroblast-based cell therapies (CYWC628, CYMS101, CybroCell) in regenerative medicine; directly matches Biotech - Cell Therapy.
|
$14.03M |
$0.35
+3.02%
|
|
ADGM
Adagio Medical Holdings, Inc.
ADGM is a medical technology company whose core offerings are medical devices/biometrics for cardiac ablation.
|
$14.00M |
$0.95
+2.09%
|
|
AMS
American Shared Hospital Services
AMS is directly operating outpatient radiation therapy centers (Direct Patient Services) in Rhode Island, Puebla, and other locations.
|
$14.00M |
$2.15
|
|
MRM
MEDIROM Healthcare Technologies Inc.
MOTHER Bracelet and related biometric sensing capabilities align with Medical Devices & Biometrics.
|
$13.83M |
$1.75
|
|
TPST
Tempest Therapeutics, Inc.
Tempest is a clinical-stage biotechnology company focused on oncology with lead and follow-on small molecule cancer programs.
|
$13.81M |
$3.15
-0.16%
|
|
HOTH
Hoth Therapeutics, Inc.
HT-001 (oncology supportive care) and HT-KIT/HT-ALZ pipelines place Hoth in oncology/biotech with a focused cancer therapy strategy.
|
$13.79M |
$1.04
-3.24%
|
|
ELTP
Elite Pharmaceuticals, Inc.
Elite focuses on the development, manufacture, and sale of generic drugs across a broad pipeline.
|
$13.78M |
$0.47
|
|
BLRX
BioLineRx Ltd.
BioLineRx's lead oncology asset motixafortide (APHEXDA) places the company squarely in oncology with an approved stem cell mobilization therapy and ongoing cancer indications development.
|
$13.65M |
$2.91
+1.04%
|
|
ACUT
Accustem Sciences Inc.
Company plans to offer Laboratory Testing & Advisory Services leveraging existing lab infrastructure and additional sequencing/heritage panels.
|
$13.61M |
$0.60
|
|
PVCT
Provectus Biopharmaceuticals, Inc.
VisiRose EyeCo focuses on ophthalmic topical RBS (PV-305) for infectious keratitis, an ophthalmic drug product.
|
$13.60M |
$0.06
|
|
THAR
Tharimmune, Inc.
THAR directly develops monoclonal antibody therapeutics (e.g., TH023 and IO assets HS1940/HS3215), fitting Monoclonal Antibody Therapeutics.
|
$13.53M |
$2.94
-0.68%
|
|
PETV
PetVivo Holdings, Inc.
PetVivo's Spryng is a veterinarian-administered medical device/biomaterial for osteoarthritis in dogs and horses.
|
$13.53M |
$0.94
|
|
CFOO
China Foods Holdings Ltd.
The company provides customized wellness consultation programs and related services.
|
$13.45M |
$0.66
|
|
SNSE
Sensei Biotherapeutics, Inc.
Sensei's lead asset targets oncology/cancer indications, fitting the Biotech - Oncology category.
|
$13.17M |
$11.11
-4.31%
|
|
NXGL
NEXGEL, Inc.
NXGEL generates revenue from contract manufacturing of hydrogel-based medical and consumer products.
|
$12.99M |
$1.71
-1.72%
|
|
ZCMD
Zhongchao Inc.
ZCMD provides healthcare information services and patient management systems to healthcare professionals and institutions, fitting Healthcare Services & Facilities.
|
$12.63M |
$0.48
+1.46%
|
|
EVTV
Envirotech Vehicles, Inc.
Medical Device Consumables: Medical supplies segment with related-party sales and cost-plus pricing indicating consumable offerings.
|
$12.53M |
$3.56
+10.22%
|
|
CRIS
Curis, Inc.
Curis's core business is oncology-focused biotech developing cancer therapies, anchored by emavusertib.
|
$12.44M |
$0.99
+4.22%
|
|
TRIB
Trinity Biotech plc
Directly manufactures glucose monitoring hardware (CGM) and wearable biosensors with an accompanying data platform.
|
$12.36M |
$0.69
-3.17%
|
|
HIGR
Hi-Great Group Holding Company
KRAS gene license places HIGR in Biotech - Oncology, an oncology-focused biotech asset.
|
$12.30M |
$0.12
|
|
BOLT
Bolt Biotherapeutics, Inc.
Bolt is a clinical-stage biotech focused on oncology immunotherapies, making 'Biotech - Oncology' a core investable theme.
|
$12.21M |
$6.40
-8.31%
|
|
LIPO
Lipella Pharmaceuticals Inc.
Lipella's core metastable liposome drug delivery platform enables targeted, localized mucosal drug formulations.
|
$12.20M |
$0.31
|
|
SYBX
Synlogic, Inc.
PKU is a rare metabolic disease and Synlogic's lead programs target rare diseases via a synthetic biology platform.
|
$12.17M |
$1.05
+0.96%
|
|
NXL
Nexalin Technology, Inc.
Core product is non-invasive neuromodulation devices for brain stimulation (Gen-2 SYNC, Gen-3 HALO).
|
$12.02M |
$0.70
+1.26%
|
|
INAB
IN8bio, Inc.
INAB's core products are gamma-delta T cell therapies (INB-100, INB-200) and preclinical programs, a direct cell therapy offering.
|
$11.76M |
$2.58
+10.99%
|
|
CLRB
Cellectar Biosciences, Inc.
Core product category: radiopharmaceuticals developed and marketed by Cellectar as radioconjugate therapies.
|
$11.46M |
$3.62
-0.82%
|
|
COCP
Cocrystal Pharma, Inc.
Cocrystal Pharma is actively developing antiviral small-molecule therapeutics (CC-42344, CDI-988, CC-31244) for influenza, norovirus/coronavirus, and HCV.
|
$11.39M |
$1.11
+0.45%
|
Showing page 33 of 38 (3753 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
